Company Profiles

driven by the PitchBook Platform

Innocrin Pharmaceuticals

Innocrin Pharmaceuticals
2014 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Accelerator/Inc LATEST DEAL TYPE
$28M TOTAL AMOUNT RAISED
9 INVESTORS
Description

Developer of oral inhibitors designed to treat advanced breast and prostate cancer. The company's oral inhibitors consists of oral CYP17 lyase inhibitors for the treatment of castration-resistant prostate cancer (CRPC) and potentially in other hormonally-driven conditions such as breast cancer, endometriosis or congenital adrenal hyperlplasia.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Primary Office
4505 Emperor Boulevard
Suite 315
Durham, NC 27703
United States

+1 (919) 237-9536
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Innocrin Pharmaceuticals’s full profile, request a free trial.

Innocrin Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Accelerator/Incubator $28M Completed Generating Revenue
1. Later Stage VC (Series D) 14-Apr-2015 0000 0000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding request access »

Innocrin Pharmaceuticals Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
A&B Equity Holdings Other Minority 000 0000 000000 0
Astellas Venture Management Corporate Venture Capital Minority 000 0000 000000 0
Eshelman Ventures Venture Capital Minority 000 0000 000000 0
Hatteras Venture Partners Venture Capital Minority 000 0000 000000 0
Intersouth Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Innocrin Pharmaceuticals Executive Team (5)

Name Title Board
Seat
Contact
Info
Fred Eshelman Chief Executive Officer & Board Member
Charles Osborne Jr. Chief Financial Officer & Corporate Secretary
Joel Eisner Ph.D Vice President, Clinical Operations
Ronald Fleming Vice President, Translational Research
Edwina Baskin-Bey MD Chief Medical Officer

Innocrin Pharmaceuticals Board Members (10)

Name Representing Role Since Contact
Info
Andrew von Eschenbach MD Self Board Member 000 0000
Douglas Reed MD Hatteras Venture Partners Chairman 000 0000
Fred Eshelman Innocrin Pharmaceuticals Chief Executive Officer & Board Member 000 0000
Kristopher Wood Lurie Holdings Board Member 000 0000
Richard Kent MD Intersouth Partners Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »